Anaveon to raise CHF 110m in oversubscribed Series B financing

Anaveon AG ("Anaveon"), a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. In connection with the Series B financing, Jasper Bos (Forbion), Tim Anderson (Cowen) and Denis Patrick (Pfizer Ventures) will join the Anaveon Board at closing, which is expected before year end. Proceeds from this financing will enable the Company to pursue multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, and to grow the pipeline into new indications.

VISCHER advises Anaveon on all legal and tax issues related to the transaction. The VISCHER team includes Christian Wyss (Partner, Corporate/M&A), Nadia Tarolli (Partner, Tax), Sebastian Flückiger (Senior Associate, Corporate/M&A), Luzius Zumstein (Senior Associate, Corporate/M&A), Delia Fehr-Bosshard (Managing Associate, Intellectual Property) and Christoph Enz (Associate, Corporate/M&A).

Press release

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk